Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Moore Kuehn, PLLC Encourages Milacron Holdings Corp. (MCRN), Ecology & Environmental, Inc. (EEI), Pivotal Software, Inc. (PVTL), and Dova Pharmaceuticals, Inc. (DOVA) Investors to Contact...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Dova Pharmaceuticals, Inc. PR Newswire NEW YORK, Oct. 4, 2019 NEW YORK, Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches...
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Dova Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Swedish Orphan Biovitrum AB PR Newswire MILWAUKEE, Sept. 30...
Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET® for chemotherapy-induced thrombocytopenia...
DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019...
DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present...
DURHAM, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019...
DOPTELET® (avatrombopag) approved by U.S. Food and Drug Administration (FDA) for treatment of chronic immune thrombocytopenia (ITP); commercial launch occurred mid-JulyDOPTELET approved by...
DURHAM, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, August 6, 2019 at 9:00 a.m. ET to discuss second quarter 2019...
DURHAM, N.C., July 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
